A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma

Completed · Not applicable

Conditions studied: Retinoblastoma

In brief

Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually safe. In recent years, there has been much interest in providing highly focused (focal) chemotherapy to a diseased organ including the liver, brain, and eye. With focused chemotherapy, the chemotherapy drugs are injected directly into the ophthalmic artery (the artery that supplies blood to the eye). A benefit of focal chemotherapy delivery is that it decreases the chance of toxicity to other organs such as bone marrow suppression (causing low blood counts) and the development of other cancers in the future.

Key facts

Study ID

NCT00857519

Run by

Wills Eye

People needed

10

Starts

2009-01-01

Expected to finish

2014-04-01

Last updated by the study team

2016-12-12

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced retinoblastoma in one or both eyes
• Recurrent retinoblastoma after failure of previous treatment
• No age limit (usually kids presenting with retinoblastoma present in the 1st two decades of life)
• Judged by principal investigator to be medically and physically able to undergo the procedure

You may not qualify if…

• Recurrent retinoblastoma which is treatable with other conservative measures
• Invasive retinoblastoma (retinoblastoma that has grown locally outside of the eye, for example, into the bone around the eye)

Where it is running

• Oncology Service, Wills Eye Institute — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.